ade-benchmark-corpus/ade_corpus_v2 · Datasets at Hugging Face

text stringlengths 7 742	label class label 2 classes
Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary.	1Related
Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary.	1Related
Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary.	1Related
After 5 days of treatment with IL-2, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia.	1Related
After 5 days of treatment with IL-2, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia.	1Related
After 5 days of treatment with IL-2, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia.	1Related
OBJECTIVE: To report a case of cutaneous and hematologic toxicity in a patient treated with IL-2.	1Related
Subcutaneous IL-2 is safe and well tolerated, with a mortality rate <3%.	1Related
Toxic epidermal necrolysis associated with interleukin-2.	1Related
A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.	1Related
Gelofusine allergy--the need for identification jewellery.	1Related
The authors describe valproate-induced hyperammonemia and mental status changes in an 88-year-old man, the first known reported case in an elderly patient.	1Related
The authors describe valproate-induced hyperammonemia and mental status changes in an 88-year-old man, the first known reported case in an elderly patient.	1Related
Valproate-induced hyperammonemia as a cause of altered mental status.	1Related
Valproate-induced hyperammonemia as a cause of altered mental status.	1Related
Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas.	1Related
The epivodes of NMS occured under treatment with clozapine, risperidone, and amisulpride.	1Related
The epivodes of NMS occured under treatment with clozapine, risperidone, and amisulpride.	1Related
The epivodes of NMS occured under treatment with clozapine, risperidone, and amisulpride.	1Related
A 73-year-old woman presented with fever and cough 2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia (CLL).	1Related
A 73-year-old woman presented with fever and cough 2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia (CLL).	1Related
Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine.	1Related
Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine.	1Related
Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine.	1Related
Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature.	1Related
Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature.	1Related
This case extends the spectrum of fludarabine pulmonary toxicity to include pulmonary nodules.	1Related
This case extends the spectrum of fludarabine pulmonary toxicity to include pulmonary nodules.	1Related
To our knowledge, four cases of interstitial pneumonitis associated with fludarabine have been reported in medical literature.	1Related
Epoprostenol may be associated rarely with severe erythroderma.	1Related
Severe erythroderma as a complication of continuous epoprostenol therapy.	1Related
We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.	1Related
We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.	1Related
We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.	1Related
We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.	1Related
We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.	1Related
A 50-year-old diabetic and hypertensive male patient is reported who had ticlopidine-induced marrow aplasia partially responsive to colony-stimulating factors and corticosteroids, but experienced complete recovery with cyclosporine.	1Related
There is no consensus on the treatment of ticlopidine-induced marrow aplasia.	1Related
Ticlopidine-induced marrow aplasia treated with cyclosporine.	1Related
A 53-year-old man developed lower leg edema 4 weeks after rosiglitazone was increased from 4 mg once/day to 4 mg twice/day.	1Related
A 75-year-old man developed bilateral lower leg edema 6 months after switching from troglitazone to pioglitazone.	1Related
A 77-year-old man developed ankle, hand, and facial swelling 2 weeks after starting rosiglitazone.	1Related
Two cases of polymorphic ventricular tachycardia induced by the administration of verapamil against paroxysmal supraventricular tachycardia.	1Related
Verapamil is widely used for the termination of paroxysmal supraventricular tachycardia (PSVT) with little proarrhythmic effect.	1Related
We describe two cases of PSVT that changed to non-sustained polymorphic ventricular tachycardia after administration of verapamil.	1Related
Epsilon-aminocaproic acid and renal complications: case report and review of the literature.	1Related
Neonatal mydriasis: intravenous lidocaine adverse reaction.	1Related
We present a neonate with a seizure disorder who acutely developed pupillary mydriasis secondary to lidocaine overdose.	1Related
We suggest adding this side effect to the list of untoward effects of lidocaine and to the differential diagnosis of fixed dilated pupils in neonates treated with lidocaine.	1Related
Myelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with 2-deoxycoformycin.	1Related
Myelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with 2-deoxycoformycin.	1Related
To the best of our knowledge only two previous cases of AML have been linked to treatment of HCL with purine analogs, both with 2-chlorodeoxyadenosine.	1Related
CONCLUSIONS: Peripheral administration of low-dose vasopressin for septic shock should be discouraged because of the risk of ischemic skin complications.	1Related
OBJECTIVE: To describe a case of severe skin necrosis resulting from peripheral intravenous administration of low-dose vasopressin in a patient with catecholamine-resistant septic shock.	1Related
Skin necrosis after extravasation of low-dose vasopressin administered for septic shock.	1Related
Mitomycin-C induced hemolytic uremic syndrome: a case report.	1Related
Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.	1Related
Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.	1Related
Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.	1Related
We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.	1Related
We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.	1Related
Drug-induced mammary hyperplasias have been reported as rare complications of D-penicillamine and Neothetazone.	1Related
Drug-induced mammary hyperplasias have been reported as rare complications of D-penicillamine and Neothetazone.	1Related
Gigantomastia induced by bucillamine.	1Related
Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to D-penicillamine, which was the subject of an abundance of reports of mammary hyperplasia.	1Related
Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to D-penicillamine, which was the subject of an abundance of reports of mammary hyperplasia.	1Related
The authors report the first case of bucillamine-induced giant mammary hyperplasia.	1Related
The authors describe three families in whom the occurrence of FVS in all the siblings strongly suggests hereditary susceptibility to valproic acid-induced adverse outcome.	1Related
The fetal valproate syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.	1Related
The fetal valproate syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.	1Related
The fetal valproate syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.	1Related
The fetal valproate syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.	1Related
The fetal valproate syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.	1Related
Valproate embryopathy in three sets of siblings: further proof of hereditary susceptibility.	1Related
Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.	1Related
We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.	1Related
We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.	1Related
The first case concerns a 70-year-old man who developed severe aplastic anemia 7 weeks after treatment with 500 mg of ticlopidine daily.	1Related
The second was an 82-year-old man receiving ticlopidine for 2 years when, during a febrile episode, he was found neutropenic with marrow aplasia.	1Related
The second was an 82-year-old man receiving ticlopidine for 2 years when, during a febrile episode, he was found neutropenic with marrow aplasia.	1Related
Ticlopidine-induced aplastic anemia (TIAA) is considered very uncommon.	1Related
Ticlopidine-induced aplastic anemia (TIAA) is considered very uncommon.	1Related
Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases.	1Related
When the data of the 57 patients are evaluated, a reversible direct cytotoxic effect of ticlopidine on the pluripotent/bipotent hematopoietic progenitor stem cell is proposed.	1Related
Fixed drug eruption to rofecoxib.	1Related
Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.	1Related
Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.	1Related
A patient who had been treated with large doses of thyroid hormone for several years developed features of secondary hypothyroidism after thyroid hormone withdrawal.	1Related
BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported.	1Related
BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported.	1Related
BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported.	1Related
BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported.	1Related
BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported.	1Related
CONCLUSION: There are only a few confirmed cases of gemcitabine-associated HUS despite the widespread use of the drug.	1Related
Gemcitabine-associated hemolytic-uremic syndrome.	1Related
Mean time between initiation of gemcitabine therapy and onset of HUS was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of gemcitabine.	1Related
Mean time between initiation of gemcitabine therapy and onset of HUS was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of gemcitabine.	1Related
METHODS: A case is presented of a 45-year-old woman on prolonged gemcitabine treatment for ovarian cancer who developed HUS and recovered after drug discontinuation.	1Related
RESULTS: Including our own patient, a total of 26 cases of gemcitabine-associated HUS were identified.	1Related
An amiodarone optic neuropathy has been described.	1Related

Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary.

1Related

Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary.

1Related

Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary.

1Related

After 5 days of treatment with IL-2, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia.

1Related

After 5 days of treatment with IL-2, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia.

1Related

After 5 days of treatment with IL-2, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia.

1Related

OBJECTIVE: To report a case of cutaneous and hematologic toxicity in a patient treated with IL-2.

1Related

Subcutaneous IL-2 is safe and well tolerated, with a mortality rate <3%.

1Related

Toxic epidermal necrolysis associated with interleukin-2.

1Related

A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.

1Related

Gelofusine allergy--the need for identification jewellery.

1Related

The authors describe valproate-induced hyperammonemia and mental status changes in an 88-year-old man, the first known reported case in an elderly patient.

1Related

The authors describe valproate-induced hyperammonemia and mental status changes in an 88-year-old man, the first known reported case in an elderly patient.

1Related

Valproate-induced hyperammonemia as a cause of altered mental status.

1Related

Valproate-induced hyperammonemia as a cause of altered mental status.

1Related

Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas.

1Related

The epivodes of NMS occured under treatment with clozapine, risperidone, and amisulpride.

1Related

The epivodes of NMS occured under treatment with clozapine, risperidone, and amisulpride.

1Related

The epivodes of NMS occured under treatment with clozapine, risperidone, and amisulpride.

1Related

A 73-year-old woman presented with fever and cough 2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia (CLL).

1Related

A 73-year-old woman presented with fever and cough 2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia (CLL).

1Related

Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine.

1Related

Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine.

1Related

Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine.

1Related

Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature.

1Related

Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature.

1Related

This case extends the spectrum of fludarabine pulmonary toxicity to include pulmonary nodules.

1Related

This case extends the spectrum of fludarabine pulmonary toxicity to include pulmonary nodules.

1Related

To our knowledge, four cases of interstitial pneumonitis associated with fludarabine have been reported in medical literature.

1Related

Epoprostenol may be associated rarely with severe erythroderma.

1Related

Severe erythroderma as a complication of continuous epoprostenol therapy.

1Related

We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.

1Related

We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.

1Related

We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.

1Related

We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.

1Related

We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.

1Related

A 50-year-old diabetic and hypertensive male patient is reported who had ticlopidine-induced marrow aplasia partially responsive to colony-stimulating factors and corticosteroids, but experienced complete recovery with cyclosporine.

1Related

There is no consensus on the treatment of ticlopidine-induced marrow aplasia.

1Related

Ticlopidine-induced marrow aplasia treated with cyclosporine.

1Related

A 53-year-old man developed lower leg edema 4 weeks after rosiglitazone was increased from 4 mg once/day to 4 mg twice/day.

1Related

A 75-year-old man developed bilateral lower leg edema 6 months after switching from troglitazone to pioglitazone.

1Related

A 77-year-old man developed ankle, hand, and facial swelling 2 weeks after starting rosiglitazone.

1Related

Two cases of polymorphic ventricular tachycardia induced by the administration of verapamil against paroxysmal supraventricular tachycardia.

1Related

Verapamil is widely used for the termination of paroxysmal supraventricular tachycardia (PSVT) with little proarrhythmic effect.

1Related

We describe two cases of PSVT that changed to non-sustained polymorphic ventricular tachycardia after administration of verapamil.

1Related

Epsilon-aminocaproic acid and renal complications: case report and review of the literature.

1Related

Neonatal mydriasis: intravenous lidocaine adverse reaction.

1Related

We present a neonate with a seizure disorder who acutely developed pupillary mydriasis secondary to lidocaine overdose.

1Related

We suggest adding this side effect to the list of untoward effects of lidocaine and to the differential diagnosis of fixed dilated pupils in neonates treated with lidocaine.

1Related

Myelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with 2-deoxycoformycin.

1Related

Myelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with 2-deoxycoformycin.

1Related

To the best of our knowledge only two previous cases of AML have been linked to treatment of HCL with purine analogs, both with 2-chlorodeoxyadenosine.

1Related

CONCLUSIONS: Peripheral administration of low-dose vasopressin for septic shock should be discouraged because of the risk of ischemic skin complications.

1Related

OBJECTIVE: To describe a case of severe skin necrosis resulting from peripheral intravenous administration of low-dose vasopressin in a patient with catecholamine-resistant septic shock.

1Related

Skin necrosis after extravasation of low-dose vasopressin administered for septic shock.

1Related

Mitomycin-C induced hemolytic uremic syndrome: a case report.

1Related

Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.

1Related

Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.

1Related

Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.

1Related

We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.

1Related

We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.

1Related

Drug-induced mammary hyperplasias have been reported as rare complications of D-penicillamine and Neothetazone.

1Related

Drug-induced mammary hyperplasias have been reported as rare complications of D-penicillamine and Neothetazone.

1Related

Gigantomastia induced by bucillamine.

1Related

Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to D-penicillamine, which was the subject of an abundance of reports of mammary hyperplasia.

1Related

Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to D-penicillamine, which was the subject of an abundance of reports of mammary hyperplasia.

1Related

The authors report the first case of bucillamine-induced giant mammary hyperplasia.

1Related

The authors describe three families in whom the occurrence of FVS in all the siblings strongly suggests hereditary susceptibility to valproic acid-induced adverse outcome.

1Related